Last updated: February 25, 2026
What is the drug associated with NDC 68180-0722?
NDC 68180-0722 corresponds to Sovaldi (sofosbuvir), an antiviral medication developed by Gilead Sciences. It treats chronic hepatitis C virus (HCV) infection, including genotypes 1 through 4.
Market Overview
Current Market Size
- The global hepatitis C virus (HCV) treatment market was valued at approximately $12 billion in 2022.
- The U.S. market accounts for roughly 50% of this, driven by high prevalence and reimbursement coverage.
- Gilead's Sovaldi maintains a dominant position, with estimated sales of $3.3 billion in 2022, despite competition from newer therapies.
Market Drivers
- High HCV prevalence in the U.S.: Estimated at 2.4 million infected individuals.
- Increasing screening efforts lead to more diagnosed cases.
- The arrival of highly effective direct-acting antiviral (DAA) regimens reduces treatment durations to 8–12 weeks, increasing patient throughput.
- Reimbursement policies favor usage, though drug pricing remains a concern for payers.
Competitive Landscape
| Drug |
Company |
Indications |
Approvals |
Market Share (Estimate) |
| Sovaldi (sofosbuvir) |
Gilead Sciences |
HCV, Genotypes 1–4 |
2013 |
60% |
| Harvoni (ledipasvir/sofosbuvir) |
Gilead Sciences |
HCV, Genotypes 1–4 |
2014 |
30% |
| Epclusa (sofosbuvir/velpatasvir) |
Gilead Sciences |
All genotypes |
2016 |
10% |
| Zepatier (elbasvir/grazoprevir) |
Merck |
HCV, Specific genotypes |
2016 |
<5% |
Market Challenges
- Pricing pressure from payers and government programs.
- Competition from generic and biosimilar products as patents expire.
- Treatment access disparities across regions.
Price Analysis and Projections
Current Price Points
- List Price: Approximately $84,000 for a 12-week course, translating to $7,000 per week.
- Reimbursement: Payers often negotiate discounts, reducing net prices by 50–70% depending on volume and coverage agreements.
- Average Selling Price (ASP): Estimated in the $40,000–$60,000 range per treatment course after discounts.
Historical Pricing Trends
| Year |
Average Price per Course |
Notes |
| 2014 |
$84,000 |
Initial launch price |
| 2017 |
$50,000–$60,000 |
After generic threat begins |
| 2020 |
$40,000–$45,000 |
Payers push for lower prices |
Future Price Projections (Next 5 Years)
| Year |
Estimated Price Range |
Factors Influencing Price |
| 2023 |
$35,000–$45,000 |
Increasing biosimilar presence, discounts |
| 2024–2025 |
$30,000–$40,000 |
Patent expirations, competition, policy shifts |
| 2026–2027 |
$25,000–$30,000 |
Expanded biosimilar volume, negotiated discounts |
Impact of Patent Expiration
- Gilead’s key patents for Sovaldi expire in 2026–2027 in the U.S.
- Biosimilars and generics expected to enter markets starting in 2026, leading to price erosion estimated at 40–60%.
Regulatory and Policy Influences
- The U.S. government has negotiated significant discounts for Medicaid and Medicare.
- International markets vary; generic versions available in Europe and low-income countries at substantially reduced prices.
Conclusion
The outlook for NDC 68180-0722 indicates declining prices driven by patent expiration, increased competition, and policy pressures. The market remains sizable, supported by ongoing HCV screening and treatment efforts, but margins are expected to tighten.
Key Takeaways
- Current net prices for Sovaldi are projected to decline 25–50% over the next five years.
- Patent expiration between 2026 and 2027 will accelerate price erosion.
- Competition from biosimilars and generics will be the primary factor influencing downward price pressure.
- Market growth hinges on increasing diagnosis rates and expanding access, especially in low- and middle-income countries.
- Market share is likely to shift towards newer combination therapies with broader genotype coverage and lower cost structures.
FAQs
Q1: How does patent expiration affect Sovaldi’s pricing?
Patent expiry allows biosimilars and generics, which typically sell at lower prices, to enter the market. This competition usually results in significant price reductions—up to 60%—over subsequent years.
Q2: Will Sovaldi remain market-dominant after patent expiration?
Gilead may retain some market share through brand recognition and manufacturing efficiencies. However, generics will dominate price-sensitive segments, drastically reducing Sovaldi’s sales share.
Q3: How are reimbursement policies influencing current prices?
Payers negotiate discounts and formulary placements, often paying less than list prices. Policy shifts favor cost-effective treatments, further pressure on the net prices.
Q4: What impact do newer HCV therapies have on the market?
Newer regimens offer similar or improved efficacy, shorter treatment durations, and fewer side effects. These factors can erode Sovaldi’s market share and impact its pricing.
Q5: What regions are most affected by price declines?
The U.S. and European markets see the steepest price declines due to increased competition, whereas low-income countries benefit from access programs and lower-priced generics.
References
- MarketWatch. (2023). Hepatitis C virus treatment market size and forecasts.
- Evaluate Pharma. (2022). 2022 Global sales data for hepatitis C therapies.
- Gilead Sciences. (2022). Annual report and product pipeline.
- IQVIA. (2022). Global healthcare market projections.
- U.S. Food and Drug Administration. (2023). Patent expiration dates and biosimilar approvals.
